PLYX is Polaryx Therapeutics, Inc. (Healthcare) — a non-dividend-paying stock. Trading at $2.04. Market cap: $102M.
Stock snapshot
| Price | $2.04 |
| Market cap | $102M |
| Sector | Healthcare |
| Exchange | NCM |
| Pays dividend | No |
About PLYX
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
Related non-dividend companies
Other non-dividend stocks investors research alongside PLYX. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is PLYX's current stock price?
PLYX (Polaryx Therapeutics, Inc.) is currently trading at $2.04.
Does PLYX pay a dividend?
PLYX (Polaryx Therapeutics, Inc.) does not currently pay a regular dividend.
Track PLYX in DiviDrip
Add PLYX to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search PLYX and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-03. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.